1. Mechanism of Action and Pharmacokinetics of Biologics
Alan C. Moss
2. Anti-tumor Necrosis Factor Agents in Ulcerative Colitis
Kindra Clark-Snustad, Ives Hot, Scott Lee
3. Anti-tumor Necrosis Factor Agents in Crohn’s Disease
Byron P. Vaughn
4. Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease
Sarah Flier
5. Use of Biologics in the Postoperative Management of Crohn’s Disease
Benjamin H. Click, Miguel Reguiero
6. Biologics in Pregnancy and Breastfeeding
Jill K. J. Gaidos, Sunanda V. Kane
7. Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease
Parambir S. Dulai, Corey A. Siegel
8. Therapeutic Drug Monitoring of Biologic Agents
Frank
I. Scott, Mark T. Osterman
9. Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks
Afrin Kamal, Bret Lashner
10. Cessation of Biologics – Can it be Done?
Hang Hock Shim, Cynthia H. Seow
11. Biologic Therapy in Pediatric Inflammatory Bowel Disease
Sona Patel, Jennifer Strople
12. Infectious Complications of Biologics
Renée M. Marchioni Beery, Joshua R. Korzenik
13. Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy
Julia Hughes, Millie D. Long
14. Non-infectious and Non-malignant Complications of Biologics
Raymond Cross
15. Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances
Asher Kornbluth
16.
Anti-Integrin Agents in IBD: Efficacy and Risk of Complications
Jimmy K. Limdi, Francis A. Farraye
17. Novel Agents in Inflammatory Bowel Disease
Fernando Velayos
18. Quality, Safety, and Practical Considerations of Using Biologic Therapies
Gil Melmed
